Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2001-05-24
2008-11-04
Burkhart, Michael (Department: 1633)
Chemistry: molecular biology and microbiology
Vector, per se
C424S093200, C424S093600, C514S04400A, C435S235100
Reexamination Certificate
active
07445929
ABSTRACT:
The present invention provides a novel adenovirus vector for which inflammation during the in vivo administration thereof is alleviated by inhibiting the induction of expression of an adenovirus gene by a foreign promoter inserted into the adenovirus genome, and a method for producing the vector, a cell line for use in the production of the recombinant adenovirus vector, or a gene therapy method using the recombinant adenovirus vector.
REFERENCES:
patent: 5534015 (1996-07-01), Kroll et al.
patent: 5591209 (1997-01-01), Kroll
patent: 5700470 (1997-12-01), Saito et al.
patent: 5707618 (1998-01-01), Armentano et al.
patent: 5731172 (1998-03-01), Saito et al.
patent: 5824544 (1998-10-01), Armentano et al.
patent: 5851806 (1998-12-01), Kovesdi et al.
patent: 5932210 (1999-08-01), Gregory et al.
patent: 6110744 (2000-08-01), Fang et al.
patent: 6210939 (2001-04-01), Gregory et al.
patent: 6312946 (2001-11-01), Yeh et al.
patent: 6328958 (2001-12-01), Amalfitano et al.
patent: 6461606 (2002-10-01), Flotte et al.
patent: 6630344 (2003-10-01), Fang et al.
patent: 2001/0006629 (2001-07-01), Gregory et al.
patent: 2001/0016192 (2001-08-01), Gregory et al.
patent: 2002/0137212 (2002-09-01), Gregory et al.
patent: 1999-0044358 (1999-06-01), None
patent: WO 95/11984 (1995-05-01), None
patent: WO 9613596 (1996-05-01), None
patent: WO 97/09439 (1997-03-01), None
patent: WO 01/23597 (2001-04-01), None
De Geest, B. et al., “Elimination of Innate Immune Responses and Liver Inflammation by PEGylation of Adenoviral Vectors and Methylprednisolone”, 2005, Human Gene Therapy, vol. 16: pp. 1-13.
Schaack,, J. “Induction and Inhibition of Innate inflammatory Responses by Adenovirus Early Region Proteins”, 2005, Viral Immun., vol. 18: pp. 79-88.
Ishii, A. et al ., “Effective Adenovirus-Mediated Gene Expression in Adult Murine Skeletal Muscle”, 1999, Muscle & Nerve, vol. 22: pp. 592-599.
McGrory, W. et al., “A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5”, 1988, Virology, vol. 163: pp. 614-617 (Abstract Only).
Patrice Yeh et al., “Efficient Dual Transcomplementation of Adenovirus E1 and E4 Regions from a 293-Derived Cell Line Expressing a Minimal E4 Functional Unit”, Journal of Virology, vol. 70, No. 1, Jan. 1996, pp. 559-565.
Nüria Morral et al., “Immune Responses to Reporter Proteins and High Viral Dose Limit Duration of Expresson with Adenoviral Vectors: Comparison of E2a Wild Type and E2a Deleted Vectors”, Human Gene Therapy, vol. 8, Jul. 1, 1997, pp. 1275-1286.
M. Lusky et al., “In Vitro and In Vivo Biology of Recombinant Adenovirus Vectors with E1, E1/E2A, or E1/E4 Deleted”, Journal of Virology, vol. 72, No. 3, Mar. 1998, pp. 2022-2032.
Wanda K. O'Neal et al., “Toxicological Comparison of E2a-Deleted and First Generation Adenoviral Vectors Expressing α1-Antitrypsin after Systemic Delivery”, Human Gene Therapy, vol. 9, Jul. 20, 1998, pp. 1587-1598.
Guang-Pin Gao et al., “Biology of Adenovirus Vectors with E1 and E4 Deletions for Liver-Directed Gene Therapy”, Journal of Virology, vol. 70, No. 12, Dec. 1996, pp. 8934-8943.
Q Wang et al., “Persistent transgene expression in mouse liver following in vivo gene transfer with a ΔE1/ΔE4 adenovirus vector”, Gene Therapy, vol. 4, 1997, pp. 393-400.
Jean-Francois Dedieu et al., “Long-Term Gene Delivery into the Livers of Immunocompetent Mice with E1/E4-Defective adenoviruses”, Journal of Virology, vol. 71, No. 6, Jun. 1997, pp. 4626-4637.
Stefan Kochanek et al., “A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase”, Proc. Natl. Acad. Sci., vol. 93, Jun. 1996, pp. 5731-5736.
Robin J. Parks et al., “A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal”, Proc. Natl. Acad. Sci., vol. 93, Nov. 1996, pp. 13565-13570.
Manal A. Morsy et al., “An adenoviral vector delected for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene”, Proc. Natl. Acad. Sci. vol. 95, Jul. 1998, pp. 7866-7871.
Gudrun Schiedner et al., “Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity”, Nature Genetics, vol. 18, Feb. 18, 1998, pp. 180-183.
Nüria Morral et al., “High Doses of a Helper-Dependent Adenoviral Vector Yield Supraphysiological Levels of α1-Antitrypsin with Negligible Toxicity”, Human Gene Therapy, vol. 9, Dec. 10, 1998, pp. 2809-2716.
Bernard G. Huyghe et al., “Purification of a Type 5 Recombinant Adenovirus Encoding Human p53 by Column Chromatography”, Human Gene Therapy, vol. 6, Nov. 1995, pp. 1403-1416.
Donna Armentano et al., “Effect of the E4 Region on the Persistence of Transgene Expression from Adenovirus Vectors”, Journal of Virology, vol. 71, No. 3, Mar. 1997, pp. 2408-2416.
Douglas E. Brough et al., “Activation of Transgene Expression by Early Region 4 Is Responsible for a High Level of Persistent Transgene Expression from Adenovirus Vectors In Vivo”, Journal of Virology, vol. 71, No. 12, Dec. 1997, pp. 9206-6213.
Calliope Caravokyri et al., “Constitutive Episomal Expression of Polypeptide IX (pIX) in a 293-Based Cell Line Complements the Deficiency of pIX Mutant Adenovirus Type 5”, Journal of Virology, vol. 69, No. 11. Nov. 1995, pp. 6627-6633.
Kathleen M. Hehir et al., “Molecular Characterization of Replication-Competent Variants of Adenovirus Vectors and Genome Modifications To Prevent Their Occurrence”, Journal of Virology, vol. 70, No. 12, Dec. 1996, pp. 8459-8467.
Valeri Krougliak et al., “Development of Cell Lines Capable of Complementing E1, E4, and Protein IX Defective Adenovirus Type 5 Mutants”, Human Gene Therapy, vol. 6, Dec. 1995, pp. 1575-1586.
Guang-Ping Gao et al., “A Cell Line for High-Yield Production of E1-Delected Adenovirus Vectors without the Emergency of Replication-Competent Virus”, Human Gene Therapy, vol. 11, Jan. 1, 2000, pp. 213-219.
Lee E. Babiss et al., “Promoter of the Adenovirus Polypeptide IX Gene: Similarity to E1B and Inactivation by Substitution of the Simian Virus 40 TATA Element”, Journal of Virology, vol. 65, No. 2, Feb. 1991, pp. 598-605.
Bruce C. Trapnell, “Adenoviral vectors for gene transfer”, Advanced Drug Delivery Reviews, vol. 12, 1993, pp. 185-199.
Nathalie Louis et al., “Cloning and Sequencing of the Cellular-Viral Junctions from the Human Adenovirus Type 5 Transformed 293 Cell Line”, Virology, vol. 233, 1997, pp. 423-429.
Frits J. Fallaux et al., “New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Competent Adenoviruses”, Human Gene Therapy, vol. 9, Sep. 1, 1998, pp. 1909-1917.
Yiping Yang et al., “Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy”, Proc. Natl. Acad. Sci., vol. 91, May 1994, pp. 4407-4411.
Robert W. Wilmott et al., “Safety of Adenovirus-Mediated Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator cDNA to the Lungs of Nonhuman Primates”, Human Gene Therapy, vol. 7, Feb. 10, 1996, pp. 301-318.
John F. Engelhardt et al., “Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver”, Proc. Natl. Acad. Sci., vol. 91, Jun. 1994, pp. 6196-6200.
Yiping Yang et al., “Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis”, Nature Genetics, vol. 7, Jul. 1994, pp. 362-369.
Heshan Zhou et al., “Development of a Complementing Cell Line and a System for Construction of Aden
Komiya Kazuo
Murata Masashi
Nakai Michio
Saito Izumu
Tohdoh Naoki
Burkhart Michael
Dainippon Sumitomo Pharma Co. ,Ltd.
Sughrue & Mion, PLLC
LandOfFree
Recombinant adenovirus vector having a reduced side effect does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant adenovirus vector having a reduced side effect, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant adenovirus vector having a reduced side effect will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4049580